Bio-Path Holdings INC

www.biopathholdings.com

NASDAQ:	BPTH
Focus:	• Drug delivery for nucleic acid drugs • Systemic diseases
Shares Outstanding:	95.6 million
Cash (12/31/16):	$9.4 million
Burn rate:	Approx. $1,000,000/qtr excluding clinical trial costs
Headquarters:	Houston, TX
President & CEO:	Peter Nielsen

COMPANY HIGHLIGHTS

- Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
- Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
- Strong IP position with composition of matter and method patents for antisense targets and manufacturing
- Lead product candidate prexigebersen (BP1001) in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
- Promising clinical data for prexigebersen shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

CORPORATE OVERVIEW

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path's lead product candidate, prexigebersen (BP1001), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. BP1002 is Bio-Path's second liposomal antisense drug candidate, and is ready for the clinic where it will be evaluated in lymphoma. Bio-Path's drug delivery technology involves microscopic-sized liposome particles that distribute nucleic acid drugs systemically and safely throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to single stranded (antisense) and double stranded (siRNA) nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where targets of disease are well characterized and systemic delivery is needed. Bio-Path also anticipates developing liposome tumor targeting technology, representing next-generation enhancements to the Company's core antisense liposome delivery technology.

PIPELINE



LEAD COMPOUND: Prexigebersen (BP1001)

The adaptor protein Growth Receptor Bound Protein-2 (Grb2) is essential to cancer cell signaling because it is utilized by oncogenic tyrosine kinases to induce cancer progression. Suppressing the function or expression of Grb2 should interrupt its vital signaling function and have a therapeutic application in cancer. Prexigebersen is a neutral-charge, liposome-incorporated antisense drug substance designed to inhibit Grb2 protein expression.

The Company is enrolling patients in a Phase II program, which will include two Phase II clinical trials of prexigebersen in combination with frontline therapy. The first of these trials is evaluating prexigebersen as a combination therapy with low dose Ara C in Acute Myeloid Leukemia (AML).

PROPRIETARY TECHNOLOGY: DNAbilize™ DNA + Neutral Lipid Delivery Technology Platform

Bio-Path's technology platform combines a stabilizing DNA backbone, P-ethoxy, with a neutral lipid carrier, which allows for efficient nucleic acid drug incorporation inside lipid particles and ease of drug delivery to diseased cells via simple intravenous infusion. Drugs developed using the DNAbilize™ platform are systemically distributed throughout the human body in contrast to competitor technologies that do not utilize this unique platform. Bio-Path's DNAbilize™ method provides distinct advantages for drug delivery including no toxicity and high uptake into target cells. To inquire about licensing, contact partnering@biopathholdings.com.

	Neutral Lipid	Cationic Lipid
Method of Action	hydrophobic/ hydrophilic	electrostatic
Drug Substance	Incorporation	electrostatic binding
Structure	multi-lamellar	complexes
Observed Preclinical Toxicity	none	Toxic due to charge
Incorporation Efficiency	High	High
Cellular Uptake	High (compared to free standing oligo)	High (compared to free standing oligo)

RECENT ACCOMPLISHMENTS AND UPCOMING MILESTONES

- Completed the Safety Segment for the Phase II for BP1001 in combination with low dose Ara C (LDAC) for AML
- Enrolled first patient in the AML Phase II clinical trial for prexigebersen with LDAC; currently 6 sites enrolling patients
- Received orphan designation in the EU from the European Medicines Agency for AML
- Expanded pre-clinical development with new target drug candidates and indications (ovarian, pancreatic, brain)
- Announced an indication outside of cancer with UT Southwestern, autoimmune collaboration in systemic lupus

CONTACTS

Peter Nielsen
President & Chief Executive Officer
(832)-742-1357

Will O'Connor
(Institutional investors/analysts)
Stern Investor Relations
(212) 362-1200
will@sternir.com

MANAGEMENT

Peter Nielsen, President and Chief Executive Officer and Chief Financial Officer

Ulrich W. Mueller, Ph.D., Chief Operating Officer

William Hahne, M.D. Vice President of Clinical Research